Reviews/Psoriasis Psoriatic Arthritis/JAK cardiovascular risk signal extends to psoriatic arthritis
Psa Jsaf · PSA-JSAF-02 · v2
The claim says a cardiovascular danger seen with these drugs in rheumatoid arthritis has been firmly proven to carry over into psoriatic arthritis. The evidence here points the other way. The studies that actually look at psoriatic arthritis or psoriatic disease found no extra heart risk, and in one large cohort the treated patients had fewer serious cardiovascular events, not more. The one study reporting a positive signal is a database analysis of spontaneous safety reports that its own authors describe as only a starting point for further work, and it is not specific to psoriatic arthritis. No randomised trial measuring hard heart outcomes in psoriatic arthritis exists in this corpus. Because the direct evidence is reassuring and the single positive signal cannot prove anything on its own, the panel judged the claim unsupported.
The three papers carrying direct psoriatic-disease cardiovascular data are null to reassuring: [1] found JAK inhibitors not associated with higher CVD risk versus TNF inhibitors (HR 0.977) or IL-17 inhibitors (HR 1.114) in PsA and axSpA over 3 years; [2] reported low thromboembolic incidence in the tofacitinib PsA programme (DVT 0.00 and 0.13, PE 0.08 and 0.00, ATE 0.31 and 0.38 per 100 patient-years); and [9] found lower MACE (HR 0.63) and no increased VTE (HR 0.80) in a psoriatic-disease-inclusive cohort. The RA cohorts [4]-[7] are likewise null. The only positive cardiovascular signal is a WHO pharmacovigilance disproportionality analysis in [8] (ROR 1.38), which its authors label hypothesis-generating and which is not disease-specific. [10] reports no results. The contested point: The evidence divides between the direct disease-population cohorts, which are null-to-reassuring ([1], [2], [9]), and the single pharmacovigilance signal in [8] (ROR 1.38 for MACE). The panel resolved this in favour of the direct data, treating the disproportionality signal as hypothesis-generating and unable to confirm risk in any population.
All 10 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Psoriasis Psoriatic Arthritis, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim asserts definitive confirmation in PsA, but the direct PsA and psoriatic-disease evidence ([1], [2], [9]) is uniformly null or reassuring — the claim is contradicted, not supported.
The only positive cardiovascular signal ([8]) is a WHO disproportionality analysis, explicitly hypothesis-generating and not PsA-specific; a reporting-odds ratio cannot definitively confirm risk in any population.
Where it remains uncertain. The sole positive signal is a non-disease-specific pharmacovigilance ROR of 1.38 [8] that its authors call hypothesis-generating, against uniformly null direct data [1], [2], [9].
Aleatory
PsA event rates in [2] are near zero (DVT 0.00, PE 0.00 in some arms), so random variation dominates and small counts cannot exclude modest risk.
Epistemic
The corpus contains no randomised PsA trial with adjudicated cardiovascular endpoints; all PsA data are observational or pooled programme rates ([1], [2], [9]).
Inferential
The ROR of 1.38 in [8] is a reporting-odds measure subject to confounding and reporting bias; inferring confirmed causal risk in PsA from it is unsupported.
The load-bearing papers from a corpus of 10, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
PsA-specific thromboembolic rates consistent with other treatments — no confirmed elevation.
“DVT, PE and ATE rates in the tofacitinib RA, PsO and PsA programmes were similar across doses and generally consistent with observational data and published rates of other treatments.”
Panel auditInternal validity: low · scope of inference: PsA patients on tofacitinib 5 or 10 mg, DVT/PE/ATE incidence rates per 100 patient-years.Key limitations: descriptive, no statistical contrast · no sample size · pooled programme and real-world data
The sole positive CV signal, but disproportionality-based, not PsA-specific, and hypothesis-generating.
“JAKis were associated with higher odds of reporting MACE (ROR 1.38 [95% CI 1.32-1.44]), mainly due to non-fatal stroke.”
Panel auditInternal validity: low · scope of inference: Spontaneous reports of MACE for JAKi versus anti-TNF in the WHO global safety database.Key limitations: not a PsA population · reporting bias · hypothesis-generating only
Large psoriatic-disease-inclusive cohort showing no increased MACE/VTE.
“These results suggest that, over 2 years, JAKis are not associated with increased risks of mortality, MACE, venous thromboembolism, or malignancy compared with conventional systemic agents in patients with skin IMIDs.”
Panel auditInternal validity: medium · scope of inference: Skin IMID patients (psoriatic disease, atopic dermatitis, alopecia areata) on JAKi versus conventional agents over 2 years, MACE, VTE, malignancy, mortality.Key limitations: psoriatic disease pooled with AD and AA · not PsA-specific · claims-database confounding
Direct PsA/axSpA cohort data refuting an elevated CV signal.
“Compared to TNFi, JAKi was not associated with higher risk of CVD (HR 0.977; 95% CI 0.632, 1.510) over 3 years in PsA or axSpA.”
Panel auditInternal validity: medium · scope of inference: People with PsA or axSpA initiating JAKi versus TNFi or IL-17i, cardiovascular disease over 3 years.Key limitations: no sample size reported · PsA and axSpA pooled · residual confounding not described
4 of 10 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus's direct PsA data is null-to-reassuring and the sole positive signal is hypothesis-generating, so an elevated CV signal is not definitively confirmed in PsA.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No PsA RCT with hard cardiovascular endpoints. Definitive confirmation requires adjudicated cardiovascular outcomes in a randomised PsA population, which the corpus entirely lacks. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised controlled trial or prospective cohort in PsA patients powered for adjudicated MACE and VTE, comparing JAK inhibitors against TNF or IL-17 inhibitors.
Open question: Does an elevated cardiovascular risk signal for JAK inhibitors exist within psoriatic arthritis specifically when measured against active comparators? Why it is still open: The direct PsA cohorts ([1], [2], [9]) are null-to-reassuring while the sole positive signal ([8]) is non-disease-specific and hypothesis-generating.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19